{"title":"探讨血浆脂蛋白分子在中国人群晚发型阿尔茨海默病中的潜在作用。","authors":"Shitao Wang, Guoshuai Luo, Qingqing Zhao, Shangrong Zhang, Zongyou Li, Jinghong Lu, Fei Wang, Daliang Sun, Hui Xu","doi":"10.1177/25424823251378973","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Evidence suggests that lipoprotein metabolism play a crucial role in Alzheimer's disease (AD). However, their involvement in late-onset AD (LOAD) remains unclear.</p><p><strong>Objective: </strong>This study aimed to uncover potential associations between lipoprotein metabolism and clinical LOAD diagnosis, cognitive function, and treatment.</p><p><strong>Methods: </strong>We performed a lipidomic analysis of plasma samples from 46 individuals with LOAD and 16 healthy controls to investigate the potential association between lipoprotein profiles, LOAD diagnosis and cognitive function. Then, we conducted a protein-protein interaction analysis to explore the potential therapeutic role of lipoprotein molecules in LOAD.</p><p><strong>Results: </strong>Our findings revealed that ApoA2 and HDL ApoA2 may be negatively associated with LOAD risk (odds ratio [OR] = 0.798, 95% confidence interval [CI] = 0.654-0.973, p = 0.026; OR = 0.785, 95% CI = 0.634-0.972, p = 0.026, respectively), while LDL-3 triglycerides showed a potential positive association (OR = 6.051, 95% CI = 1.789-20.470, p = 0.004). Additionally, HDL-4 ApoA1 may be positively correlated with cognitive function in LOAD (p = 0.047, r² = 0.087). Moreover, our findings suggest that ApoA2 may interact with targets of approved AD drugs.</p><p><strong>Conclusions: </strong>This study identifies potential key lipoprotein alterations associated with LOAD diagnosis and cognitive function, emphasizing the role of lipidomic insights in understanding and treating LOAD.</p>","PeriodicalId":73594,"journal":{"name":"Journal of Alzheimer's disease reports","volume":"9 ","pages":"25424823251378973"},"PeriodicalIF":2.8000,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12437157/pdf/","citationCount":"0","resultStr":"{\"title\":\"Exploration of the potential role of plasma lipoprotein molecules in late-onset Alzheimer's disease among the Chinese population.\",\"authors\":\"Shitao Wang, Guoshuai Luo, Qingqing Zhao, Shangrong Zhang, Zongyou Li, Jinghong Lu, Fei Wang, Daliang Sun, Hui Xu\",\"doi\":\"10.1177/25424823251378973\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Evidence suggests that lipoprotein metabolism play a crucial role in Alzheimer's disease (AD). However, their involvement in late-onset AD (LOAD) remains unclear.</p><p><strong>Objective: </strong>This study aimed to uncover potential associations between lipoprotein metabolism and clinical LOAD diagnosis, cognitive function, and treatment.</p><p><strong>Methods: </strong>We performed a lipidomic analysis of plasma samples from 46 individuals with LOAD and 16 healthy controls to investigate the potential association between lipoprotein profiles, LOAD diagnosis and cognitive function. Then, we conducted a protein-protein interaction analysis to explore the potential therapeutic role of lipoprotein molecules in LOAD.</p><p><strong>Results: </strong>Our findings revealed that ApoA2 and HDL ApoA2 may be negatively associated with LOAD risk (odds ratio [OR] = 0.798, 95% confidence interval [CI] = 0.654-0.973, p = 0.026; OR = 0.785, 95% CI = 0.634-0.972, p = 0.026, respectively), while LDL-3 triglycerides showed a potential positive association (OR = 6.051, 95% CI = 1.789-20.470, p = 0.004). Additionally, HDL-4 ApoA1 may be positively correlated with cognitive function in LOAD (p = 0.047, r² = 0.087). Moreover, our findings suggest that ApoA2 may interact with targets of approved AD drugs.</p><p><strong>Conclusions: </strong>This study identifies potential key lipoprotein alterations associated with LOAD diagnosis and cognitive function, emphasizing the role of lipidomic insights in understanding and treating LOAD.</p>\",\"PeriodicalId\":73594,\"journal\":{\"name\":\"Journal of Alzheimer's disease reports\",\"volume\":\"9 \",\"pages\":\"25424823251378973\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2025-09-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12437157/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Alzheimer's disease reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/25424823251378973\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"NEUROSCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Alzheimer's disease reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/25424823251378973","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 0
摘要
背景:有证据表明脂蛋白代谢在阿尔茨海默病(AD)中起着至关重要的作用。然而,它们在迟发性AD (LOAD)中的作用尚不清楚。目的:本研究旨在揭示脂蛋白代谢与临床负荷诊断、认知功能和治疗之间的潜在关联。方法:我们对46名LOAD患者和16名健康对照者的血浆样本进行了脂质组学分析,以研究脂蛋白谱、LOAD诊断和认知功能之间的潜在关联。然后,我们进行了蛋白-蛋白相互作用分析,以探索脂蛋白分子在LOAD中的潜在治疗作用。结果:ApoA2和HDL ApoA2可能与LOAD风险呈负相关(比值比[OR] = 0.798, 95%可信区间[CI] = 0.654-0.973, p = 0.026; OR = 0.785, 95% CI = 0.634-0.972, p = 0.026),而LDL-3甘油三酯与LOAD风险呈潜在正相关(OR = 6.051, 95% CI = 1.789-20.470, p = 0.004)。此外,HDL-4 ApoA1可能与LOAD患者的认知功能呈正相关(p = 0.047, r²= 0.087)。此外,我们的研究结果表明,ApoA2可能与已批准的AD药物靶点相互作用。结论:本研究确定了与LOAD诊断和认知功能相关的潜在关键脂蛋白改变,强调了脂质组学见解在理解和治疗LOAD中的作用。
Exploration of the potential role of plasma lipoprotein molecules in late-onset Alzheimer's disease among the Chinese population.
Background: Evidence suggests that lipoprotein metabolism play a crucial role in Alzheimer's disease (AD). However, their involvement in late-onset AD (LOAD) remains unclear.
Objective: This study aimed to uncover potential associations between lipoprotein metabolism and clinical LOAD diagnosis, cognitive function, and treatment.
Methods: We performed a lipidomic analysis of plasma samples from 46 individuals with LOAD and 16 healthy controls to investigate the potential association between lipoprotein profiles, LOAD diagnosis and cognitive function. Then, we conducted a protein-protein interaction analysis to explore the potential therapeutic role of lipoprotein molecules in LOAD.
Results: Our findings revealed that ApoA2 and HDL ApoA2 may be negatively associated with LOAD risk (odds ratio [OR] = 0.798, 95% confidence interval [CI] = 0.654-0.973, p = 0.026; OR = 0.785, 95% CI = 0.634-0.972, p = 0.026, respectively), while LDL-3 triglycerides showed a potential positive association (OR = 6.051, 95% CI = 1.789-20.470, p = 0.004). Additionally, HDL-4 ApoA1 may be positively correlated with cognitive function in LOAD (p = 0.047, r² = 0.087). Moreover, our findings suggest that ApoA2 may interact with targets of approved AD drugs.
Conclusions: This study identifies potential key lipoprotein alterations associated with LOAD diagnosis and cognitive function, emphasizing the role of lipidomic insights in understanding and treating LOAD.